Topics

  • Thymoma
  • Early lung cancer in specific groups
  • Thromboembolic events in NSCLC
  • Resistance to immune check point inhibitors
  • Immunotherapy
  • Combined treatment in stage III NSCLC
  • Metastasis
  • MSCLC: ALK mutation
  • ASCO 2020
Back to Top